Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $40.6M | $8.25M | $69.7M | $77.6M | $9.30M | $222M | $502M |
| Revenue growth | — | — | — | -79.7% | 745.1% | 11.4% | -88.0% | 2285.3% | 126.3% |
| Operating income | -$43.9M | -$184M | -$266M | -$474M | -$577M | -$512M | -$607M | -$593M | -$523M |
| Operating margin | — | — | -656.4% | -5752.0% | -827.1% | -659.6% | -6528.8% | -267.2% | -104.2% |
| Net income | -$43.8M | -$169M | -$289M | -$505M | -$586M | -$485M | -$653M | -$543M | -$733M |
| Net margin | — | — | -711.5% | -6127.9% | -841.2% | -624.2% | -7021.9% | -244.9% | -146.0% |
| EPS (diluted) | -$1.00 | -$2.12 | -$2.48 | -$3.80 | -$3.90 | -$3.26 | -$3.95 | -$2.88 | -$3.78 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.5M | -$137M | -$254M | -$400M | -$498M | -$419M | -$528M | -$521M | -$446M |
| Capital expenditures | $464K | $2.18M | $2.64M | $7.52M | $13.2M | $4.82M | $1.31M | $933K | $1.10M |
| Free cash flow | -$41.0M | -$139M | -$256M | -$407M | -$511M | -$424M | -$529M | -$522M | -$447M |
| Share buybacks | — | — | — | $75.0M | $200M | $0.00 | $0.00 | $0.00 | $48.3M |
| Dividends paid | $1.15M | — | $997K | — | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $92.0M | $436M | $364M | $356M | $394M | $377M | $376M | $681M | $570M |
| Total assets | — | $465M | $632M | $704M | $1.01B | $623M | $546M | $919M | $936M |
| Total liabilities | — | $87.6M | $156M | $596M | $1.88B | $1.87B | $1.89B | $2.38B | $3.01B |
| Long-term debt | — | $54.5M | $95.4M | $93.9M | $431M | $431M | $446M | $437M | $2.01B |
| Shareholders' equity | $85.9M | $315M | $408M | $57.9M | -$870M | -$1.25B | -$1.35B | -$1.47B | -$2.09B |
| Retained earnings | -$48.7M | -$179M | -$440M | -$889M | -$1.44B | -$1.92B | -$2.56B | -$3.10B | -$3.82B |
| Shares (wtd avg diluted) | — | 92.1M | 124M | 118M | 144M | 147M | 163M | 186M | 192M |
Every figure is extracted from BridgeBio Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.